Evidence map›Paper›PMID 35774345›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2022

Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan.

Hideki Hagiwara, Yoshiki Ito, Takashi Ohta, Yasutoshi Nozaki, Takayuki Iwamoto, Atsushi Hosui, Naoki Hiramatsu, Yuki Tahata, Ryotaro Sakamori, Hayato Hikita and 1 more

Open access · goldAbstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hideki HagiwaraDepartment of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan.ORCID https://orcid.org/0000-0002-8361-1311
Yoshiki ItoDepartment of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan.
Takashi OhtaDepartment of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan.ORCID https://orcid.org/0000-0002-1941-206X
Yasutoshi NozakiDepartment of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan.
Takayuki IwamotoDepartment of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan.
Atsushi HosuiDepartment of Gastroenterology and Hepatology Osaka Rosai Hospital Sakai Osaka Japan.
Naoki HiramatsuDepartment of Gastroenterology and Hepatology Osaka Rosai Hospital Sakai Osaka Japan.
Yuki TahataDepartment of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Osaka Japan.ORCID https://orcid.org/0000-0002-9116-7054
Ryotaro SakamoriDepartment of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Osaka Japan.ORCID https://orcid.org/0000-0002-1580-607X
Hayato HikitaDepartment of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Osaka Japan.
Norio HayashiDepartment of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan.
Kansai Rosai Hospital · JPThe University of Osaka · JPOsaka Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: The development of hepatocarcinogenesis after a sustained virological response (SVR) remains an important issue affecting the balance between treatment and occupational life of workers with chronic hepatitis C virus (HCV) infection in Japan. Here, we aimed to evaluate the hepatocellular carcinoma (HCC) reducing effect and risk factors for developing HCC after SVR in patients treated with direct-acting antiviral agents (DAAs) among the working population. Methods: We studied 2579 working patients with chronic HCV infection who achieved SVR after antiviral treatment. We compared the difference in the cumulative incidence of post-SVR HCC between the interferon (IFN)-based Results: After propensity score matching ( Conclusion: The HCC suppressing effect after SVR through DAA treatment is equivalent to that of IFN treatment in patients in the working population. Intensive follow-up is required after SVR with DAA treatment in Japanese workers with these risk factors to ensure the promotion of health and employment support.

Indexed as

hepatitis Chepatitis C virus treatmenthepatocellular carcinomasustained virological responseworking population

Identifiers

PMID35774345
PMCPMC9218520
OpenAlexW4280581579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.